A Phase 1b Study of ASP1948, Targeting an Immune Modulatory
Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors
The main purpose of the study is to determine at what dose the study drug (ASP1948) is safe and tolerated and how it is processed in the blood of participants with tumors that cannot be removed (unresectable) or have spread (metastasized) to a different part of the body.
locally-advanced (unresectable) or metastatic solid tumors
male and female subjects of 18 and older
locally advanced or metastatic solid tumor malignancy
18 - 100
Healthy Volunteers Needed
Duration of Participation
Up to 48 weeks of receiving the study drug and 45 weeks of follow-up time after completing the study drug.
Knight Clinical Trials Information Line
Astellas Pharma Global Development, Inc.